|
Bextra®
lawsuits Philadelphia.
|
On April 7, 2005 the FDA announced
that it has asked Pfizer, Inc. to withdraw
Bextra from the market "because the overall risk
versus benefit profile for the drug is unfavorable."
|
To
report any unexpected adverse or serious events associated
with the use of Bextra® contact the FDA MedWatch program at 1-800-FDA-1088 or on the
above link.
Bextra® is
a COX-2 selective agent. It is
prescribed for inflammation and pain from arthritis or menstrual
cramping. Other drugs in this class include Celebrex® and
Vioxx®. Many doctors switched patients
from Vioxx® to Bextra® when Merck voluntarily removed it from the
market due studies showing an increased risk for heart attack
and stroke.
bextra
site map
For additional information, try
these sites:
For
a free case evaluation from a Philadelphia attorney, click here:
http://www.lawforum.net/areas/bextra/pennsylvania/philadelphia/
Munley,
Munley & Cartwright, P.C. is a Pennsylvania law office which
has breaking news and information about this lawsuit http://www.munley.com/drugs/bextra.html
Click
here to read the FDA questions and answers about strengthened warnings on Bextra®
boxes http://www.fda.gov/cder/drug/infopage/bextra/bextraQA.htm
|
